The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1193
October 11, 2004
View Complete Issue         Table of Contents 2019 
Duloxetine (Cymbalta): A New SNRI for Depression
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Duloxetine (Cymbalta): A New SNRI for Depression
October 11, 2004 (Issue: 1193)
Duloxetine hydrochloride (Cymbalta - Lilly), a selective serotonin and norepinephrine reuptake inhibitor (SNRI), has been approved by the FDA for treatment of major depressive disorder in adults, and more recently for diabetic peripheral neuropathy...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Duloxetine (Cymbalta): A New SNRI for Depression
Article code: 1193a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.